^
Association details:
| Biomarker: | CXCR5 overexpression |
|---|---|
| Cancer: | Lymphoma |
| Drug: | VIP924 (KIF11 inhibitor, CXCR5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6294: CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma
Published date:
04/04/2023
Excerpt:
CXCR5-targeting ADC with KSPi payload showed high potency and superiority to other B-cell-targeted ADCs in vitro on a broad range of lymphoma cell lines. VIP924 with a novel legumain-cleavable linker showed activity in in vivo PDX models from lymphoma patients. Due to the high CXCR5 expression found in relapsed DLBCL patients, VIP924 may bring promising new treatment options for previously treated patients with lymphoma.
DOI:
10.1158/1538-7445.AM2023-6294
